A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Nelotanserin (Primary)
- Indications Dementia; Lewy body disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Axovant Sciences
- 08 Jan 2018 Results presented in an Axovant Sciences media release.
- 08 Jan 2018 Results (corrected) presented in an Axovant Sciences media release.
- 12 Dec 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History